Eye Cell

EyeCell is a clinical-stage biotechnology company and a portfolio startup of Leonhardt Ventures, specializing in regenerative medicine for the eye. The company utilizes a proprietary platform that combines bioelectric signaling sequences with biologics to stimulate the body's natural healing and regeneration processes. Its primary focus is on treating age-related macular degeneration (AMD) and glaucoma by promoting the expression of regenerative proteins such as Klotho and SDF-1. EyeCell has demonstrated vision improvement in pilot clinical studies involving over 170 patients and is currently advancing its technology through further clinical trials. The company's approach aims to provide non-invasive or minimally invasive alternatives to traditional pharmaceutical and surgical treatments for vision loss.